TY - JOUR
T1 - Ocular Manifestations and Burden Related to Sjögren Syndrome
T2 - Results of a Patient Survey
AU - Saldanha, Ian J.
AU - Bunya, Vatinee Y.
AU - McCoy, Sara S.
AU - Makara, Matthew
AU - Baer, Alan N.
AU - Akpek, Esen K.
N1 - Funding Information:
Funding/Support: The Sjögren’s Foundation funded the survey development and deployment and paid for Mr Makara's time spent working on this paper, but did not pay the other authors for the conduct of the analysis or writing the paper. Dr Bunya declares financial support from the National Eye Institute (grant number R01 EY026972 ). Dr McCoy declares funding from the Clinical and Translational Science Award ( CTSA ) program, through the National Institutes of Health National Center for Advancing Translational Sciences (NCATS) (grant number 1KL2TR002374 ). Drs Saldanha, Baer, and Akpek did not receive funding for this work. Financial Disclosures: Dr Bunya declares grant support from Bausch & Lomb (for a separate study) and consultant fees from Verily and Celularity, all outside the submitted work. Mr Makara declares employment by the Sjögren's Foundation. Dr Baer declares consultant fees from Bristol-Myers Squibb, AbbVie, Sanofi-Aventis, and Mitsubishi Tanabe Pharma America, all outside the submitted work. Dr Akpek declares grant support from Allergan, W.L. Gore & Associates, the Department of Defense, the National Institutes of Health, and EpiTech, and consultant fees from Regeneron and Novaliq, all outside the submitted work. Drs Saldanha and McCoy declare no other relevant financial disclosures. All authors attest that they meet the current ICMJE criteria for authorship.
Funding Information:
Funding/Support: The Sj?gren's Foundation funded the survey development and deployment and paid for Mr Makara's time spent working on this paper, but did not pay the other authors for the conduct of the analysis or writing the paper. Dr Bunya declares financial support from the National Eye Institute (grant number R01 EY026972). Dr McCoy declares funding from the Clinical and Translational Science Award (CTSA) program, through the National Institutes of Health National Center for Advancing Translational Sciences (NCATS) (grant number 1KL2TR002374). Drs Saldanha, Baer, and Akpek did not receive funding for this work. Financial Disclosures: Dr Bunya declares grant support from Bausch & Lomb (for a separate study) and consultant fees from Verily and Celularity, all outside the submitted work. Mr Makara declares employment by the Sj?gren's Foundation. Dr Baer declares consultant fees from Bristol-Myers Squibb, AbbVie, Sanofi-Aventis, and Mitsubishi Tanabe Pharma America, all outside the submitted work. Dr Akpek declares grant support from Allergan, W.L. Gore & Associates, the Department of Defense, the National Institutes of Health, and EpiTech, and consultant fees from Regeneron and Novaliq, all outside the submitted work. Drs Saldanha and McCoy declare no other relevant financial disclosures. All authors attest that they meet the current ICMJE criteria for authorship.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/11
Y1 - 2020/11
N2 - Purpose: To compare the burden related to dry eye with systemic symptoms of Sjögren syndrome; to estimate the burden related to ocular treatments; and to compare the impact of dry eye and extraocular manifestations of Sjögren syndrome on various aspects of patient life. Design: Cross-sectional study. Methods: We conducted a postal survey of adult patients with a history of physician-diagnosed Sjögren syndrome. Results: The survey was completed by 2,961 patients (mean age 65.1 years, standard deviation 11.7 years), most of whom were women (96%) and white (94%). Forty-one patients younger than 18 years of age were excluded. More than half (53%) experienced severe dry eye (ie, dry eye daily/almost daily with major impact on their life). Corresponding proportions for dry mouth and fatigue were 48% and 45%, respectively. Almost all patients (97%) had used nonprescription eye drops/artificial tears/ointments. Compared with patients who did not experience dry eye, those who experienced significant dry eye (ie, daily/almost daily dry eye) more often agreed that living with Sjögren syndrome made every day a challenge (adjusted odds ratio [OR] 3.81, 95% confidence interval [CI] 2.49 to 5.86) and added a significant emotional burden (adjusted OR 2.22, 95% CI 1.49 to 3.31). Adjusted ORs for the impact of dry eye were generally lower than those for fatigue, but were similar to dry mouth and considerably higher than use of systemic treatments for serious manifestations of the disease and diagnosis of lymphoma. Conclusions: Sjögren-related dry eye is more burdensome than systemic manifestations of the disease. While fatigue has the greatest impact on patient life, the impact of dry eye is comparable to that of other systemic manifestations.
AB - Purpose: To compare the burden related to dry eye with systemic symptoms of Sjögren syndrome; to estimate the burden related to ocular treatments; and to compare the impact of dry eye and extraocular manifestations of Sjögren syndrome on various aspects of patient life. Design: Cross-sectional study. Methods: We conducted a postal survey of adult patients with a history of physician-diagnosed Sjögren syndrome. Results: The survey was completed by 2,961 patients (mean age 65.1 years, standard deviation 11.7 years), most of whom were women (96%) and white (94%). Forty-one patients younger than 18 years of age were excluded. More than half (53%) experienced severe dry eye (ie, dry eye daily/almost daily with major impact on their life). Corresponding proportions for dry mouth and fatigue were 48% and 45%, respectively. Almost all patients (97%) had used nonprescription eye drops/artificial tears/ointments. Compared with patients who did not experience dry eye, those who experienced significant dry eye (ie, daily/almost daily dry eye) more often agreed that living with Sjögren syndrome made every day a challenge (adjusted odds ratio [OR] 3.81, 95% confidence interval [CI] 2.49 to 5.86) and added a significant emotional burden (adjusted OR 2.22, 95% CI 1.49 to 3.31). Adjusted ORs for the impact of dry eye were generally lower than those for fatigue, but were similar to dry mouth and considerably higher than use of systemic treatments for serious manifestations of the disease and diagnosis of lymphoma. Conclusions: Sjögren-related dry eye is more burdensome than systemic manifestations of the disease. While fatigue has the greatest impact on patient life, the impact of dry eye is comparable to that of other systemic manifestations.
UR - http://www.scopus.com/inward/record.url?scp=85089891731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089891731&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2020.05.043
DO - 10.1016/j.ajo.2020.05.043
M3 - Article
C2 - 32569739
AN - SCOPUS:85089891731
VL - 219
SP - 40
EP - 48
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
ER -